ViewPoint Therapeutics
- Company typePrivate
- Founded2014
- HeadquartersSan Francisco, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
ViewPoint Therapeutics firmographics
Firmographics- Name
- ViewPoint Therapeutics
- Website
- https://viewpointtherapeutics.com
- Company type
- Private
- Founded year
- 2014
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
ViewPoint Therapeutics industry classification
Industry- Product category
- Ophthalmology Pharmaceuticals
- akta.pro primary industry
- Ophthalmology Pharmaceuticals (HLAIAAAL)
Keywords
Where ViewPoint Therapeutics is headquartered
LocationHeadquarters
- HQ city
- San Francisco
- HQ country
- United States
- HQ region
- North America
Markets served
ViewPoint Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales
ViewPoint Therapeutics product offering
Product offeringCore offering
ViewPoint Therapeutics is a clinical-stage biopharmaceutical company developing small-molecule crystallin stabilizers intended to prevent and treat cataracts and presbyopia. The company's therapeutics work by binding to and stabilizing crystallin proteins in the eye lens, aiming to provide a non-surgical, disease-modifying treatment for age-related lens opacities and loss of lens accommodation.
Differentiator
Problem solved
Functional benefit
Products and services
- Crystallin Stabilizer Therapeutic Program A pipeline of proprietary small-molecule therapeutics designed to bind and stabilize crystallin proteins in the eye lens to prevent and treat cataracts and presbyopia, intended for licensing or partnering with pharmaceutical companies for eventual commercialization to patients via ophthalmology providers.
Companies that use ViewPoint Therapeutics
Customer profileIdeal customer profiles1 record
ViewPoint Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
ViewPoint Therapeutics partnerships and signals
Strategic signalRecent moves3 records
Expansion highlights4 records
ViewPoint Therapeutics competitors and assessment
Company assessmentDirect peers
- Orasis Pharmaceuticals: Clinical-stage ophthalmic company developing CSF-1, a low-dose pilocarpine eye drop for presbyopia. Most directly comparable peer to ViewPoint given its focus on a pharmaceutical treatment for presbyopia, the same indication ViewPoint is targeting.
- Eyenovia: Develops the Optejet microdose array print platform for delivering ophthalmic therapeutics, with programs in presbyopia (MicroLine) and myopia. Direct peer in ophthalmic drug development and delivery, targeting overlapping indications with ViewPoint.
- Ocuphire Pharma: Late clinical-stage ophthalmic company developing Nyxol (phentolamine) for presbyopia and other indications, plus APX3330 for diabetic retinopathy. Small-cap, indication-focused ophthalmic drug developer structurally similar to ViewPoint.
- EyePoint Pharmaceuticals: Develops sustained-release ocular drug delivery systems including DURYSTA (bimatoprost implant) for glaucoma. Comparable to ViewPoint as a small ophthalmic pharma R&D company pursuing disease-modifying ocular therapeutics with proprietary delivery.
Broad incumbents
- AbbVie (Allergan Aesthetics): Large pharmaceutical company that, through its Allergan acquisition, developed and commercialized Vuity (pilocarpine 1.25%), the first FDA-approved eye drop for presbyopia. Broad incumbent competing in the same presbyopia indication ViewPoint targets.
- Alcon: World's largest dedicated ophthalmic company with leading cataract-surgery, IOL, and ophthalmic pharmaceutical franchises. Acquired Aerie Pharmaceuticals and Kala Bio to expand its pharmaceutical pipeline. Broad incumbent whose surgical and pharma businesses directly overlap ViewPoint's target indications.
- Bausch + Lomb: Major global ophthalmic company with surgical, pharmaceutical, and consumer vision care franchises including IOLs, cataract surgery products, and ophthalmic drugs. Broad incumbent and a natural strategic acquirer of late-stage ophthalmic assets like ViewPoint's.
- Aerie Pharmaceuticals: Was an ophthalmic pharmaceutical company that developed Rocklatan and Rhopressa for glaucoma before being acquired by Alcon in 2022. Closely comparable specialty ophthalmic pharma R&D business model to ViewPoint.
Emerging players
- Stuart Therapeutics: Pre-clinical and early-clinical-stage company developing collagen mimetic peptides for ocular surface diseases including dry eye and corneal injury. Comparable to ViewPoint as a small, science-driven ophthalmic therapeutics R&D company.
- Nacuity Pharmaceuticals: Clinical-stage company developing N-acetylcysteine (NAC) formulations for oxidative stress-related diseases, including ophthalmic indications such as presbyopia and cataract prevention. Closely aligned mechanism (oxidative protection of lens proteins) to ViewPoint's crystallin-stabilization approach.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks6 records
Key highlights5 records
Customer concentration
ViewPoint Therapeutics social profiles
Digital presenceViewPoint Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
ViewPoint Therapeutics leadership team
Management profileNumber of profiles
Profiles4 records
ViewPoint Therapeutics funding detail
Funding detailFunding overview
Funding rounds2 records
Investors7 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
ViewPoint Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about ViewPoint Therapeutics
What does ViewPoint Therapeutics do?
ViewPoint Therapeutics is a clinical-stage biopharmaceutical company developing small-molecule crystallin stabilizers intended to prevent and treat cataracts and presbyopia. The company's therapeutics work by binding to and stabilizing crystallin proteins in the eye lens, aiming to provide a non-surgical, disease-modifying treatment for age-related lens opacities and loss of lens accommodation.
When was ViewPoint Therapeutics founded?
ViewPoint Therapeutics was founded in 2014. It employs 11 to 50 people.
Where is ViewPoint Therapeutics based?
ViewPoint Therapeutics is headquartered in San Francisco, United States, in the North America region.
Who are ViewPoint Therapeutics's main competitors?
Direct peers on record are Orasis Pharmaceuticals, Eyenovia, Ocuphire Pharma and EyePoint Pharmaceuticals. Broad incumbents are AbbVie (Allergan Aesthetics), Alcon, Bausch + Lomb and Aerie Pharmaceuticals. Emerging players are Stuart Therapeutics and Nacuity Pharmaceuticals.
Does ViewPoint Therapeutics have an API?
No public API is recorded for ViewPoint Therapeutics.
What industry is ViewPoint Therapeutics in?
ViewPoint Therapeutics's product category is Ophthalmology Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAL, Ophthalmology Pharmaceuticals.